Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OncoSil + FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- OncoSil Medical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
OncoSil + FOLFIRINOX is a combination treatment for locally advanced pancreatic cancer (LAPC). OncoSil is a brachytherapy device consisting of phosphorus-32 (P-32) microparticles that are implanted directly into the pancreatic tumor via endoscopic ultrasound (EUS) guidance. Once implanted, the microparticles deliver localized beta radiation (typically 100 Gy) to the tumor over several weeks. FOLFIRINOX is a systemic chemotherapy regimen comprising folinic acid (leucovorin), 5-fluorouracil, irinotecan, and oxaliplatin. The combination aims to provide local tumor control through targeted radiation while managing systemic disease with chemotherapy, potentially downstaging unresectable tumors for surgical resection. The treatment is being evaluated in clinical trials such as the TRIPP-FFX study.
- Other names
- P-32 microparticles + FOLFIRINOXphosphorus-32 microparticles + FOLFIRINOX
02
Targets
TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on OncoSil + FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoSil + FOLFIRINOX.